Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
166
Recruiting, any sponsor type, condition "urothelial carcinoma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting166
- Completed335
166 trials
Showing 1 to 25, recently updated first.
Haihua YuanAcademic, hospital or other
NCT07631871 · 10 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2029
Drug: Zanidatamab · For: Neoplasms; Solid Tumors; HER2 Positive Solid Tumor and 7 more
Sites: Shanghai, China
IDEAYA BiosciencesIndustry
NCT07277413 · 570 participants (planned) · Start Mar 4, 2026 · Primary completion Apr 30, 2028
Drug: IDE892; IDE397 and 1 more · For: Bladder Cancer; Mesothelioma; Pleural Mesothelioma and 5 more
Sites: Goodyear, Arizona; Phoenix, Arizona; Duarte, California · 26 sites in all
PfizerPfizer (PFE)
NCT07421700 · 132 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 28, 2027
Drug: PF-08634404; Enfortumab Vedotin · For: Urothelial Cancer; Advanced/Metastatic Urothelial Cancer; Urothelial Carcinoma
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 198 sites in all
Haihua YuanAcademic, hospital or other
NCT07631884 · 15 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2028
Drug: Trastuzumab Rezetecan · For: Solid Tumors; Neoplasms (Cancer / Tumors); Advanced Malignant Solid Neoplasm and 13 more
Sites: Shanghai, China
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)Pivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07566156 · 390 participants (planned) · Start May 11, 2026 · Primary completion Mar 31, 2030
Drug: Enfortumab vedotin; Cisplatin and 4 more · For: Urothelial Cancer; Urinary Bladder Neoplasms
Sites: Little Rock, Arkansas; Santa Barbara, California; Aurora, Colorado · 37 sites in all
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT07439120 · 10 participants (planned) · Start Apr 13, 2026 · Primary completion Dec 31, 2026
Drug: ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 · For: Urothelial Carcinoma (UC)
Sites: Shanghai, China
National Cancer Institute (NCI)NIH
NCT03866382 · 314 participants (planned) · Start May 13, 2019 · Primary completion Feb 28, 2027
Drug: Cabozantinib S-malate; Ipilimumab and 1 more · For: Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 582 sites in all
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT04628767 · 131 participants (planned) · Start Nov 12, 2021 · Primary completion Sep 30, 2027
Drug: Cisplatin; Doxorubicin Hydrochloride and 5 more · For: Renal Pelvis and Ureter Urothelial Carcinoma
Sites: Kingman, Arizona; Fort Smith, Arkansas; Little Rock, Arkansas · 259 sites in all
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyPivotal-lookingRecruiting
SystImmune Inc.Industry
NCT07869836 · 520 participants (planned) · Start Nov 2026 · Primary completion Dec 2028
Drug: T-Bren, Dose level 1; T-bren, Dose level 2 and 1 more · For: Urothelial Cancer; Metastatic Urothelial Cancer; Bladder Cancer and 9 more
Sites: Macon, Georgia; ‘Aiea, Hawaii; Fredericksburg, Virginia
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT05321316 · 40 participants (planned) · Start May 31, 2025 · Primary completion Dec 2026
Drug: 18F-FDG · For: Urothelial Carcinoma; Breast Cancer; Lung Cancer and 3 more
Sites: Beijing, China
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07419295 · 590 participants (planned) · Start Apr 23, 2026 · Primary completion Jul 27, 2029
Drug: Sacituzumab tirumotecan; Vinflunine and 4 more · For: Bladder Cancer
Sites: Newport Beach, California; Aurora, Colorado; Highlands Ranch, Colorado · 117 sites in all
Aktis Oncology, Inc.Industry
NCT07020117 · 150 participants (planned) · Start Aug 22, 2025 · Primary completion Dec 2027
Drug: [225Ac]Ac-AKY-1189 (therapeutic); [64Cu]Cu-AKY-1189 (imaging) · For: Urothelial Carcinoma Bladder; Triple Negative Breast Cancer (TNBC); Hormone Receptor Positive Breast Adenocarcinoma and 4 more
Sites: Duarte, California; Irvine, California; Miami, Florida · 14 sites in all
LG ChemIndustry
NCT06332755 · 76 participants (planned) · Start Jun 5, 2024 · Primary completion Nov 2027
Drug: Phase 1a: LB-LR1109; Phase 1b: LB-LR1109 and Atezolizumab · For: Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC) and 2 more
Sites: Fairfax, Virginia
KaliVir ImmunotherapeuticsIndustry
NCT06444815 · 60 participants (planned) · Start Sep 16, 2024 · Primary completion Sep 30, 2027
Drug: VET3-TGI; Atezolizumab · For: Solid Tumor, Adult; Microsatellite Stable Colorectal Cancer; Head and Neck Squamous Cell Carcinoma and 10 more
Sites: Los Angeles, California; Orange, California; Miami, Florida · 8 sites in all
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06524544 · 320 participants (planned) · Start Dec 2, 2025 · Primary completion Dec 31, 2030
Drug: Carboplatin; Cisplatin and 5 more · For: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
Sites: Phoenix, Arizona; Irvine, California; Orange, California · 163 sites in all
University of Michigan Rogel Cancer CenterAcademic, hospital or other
NCT07630155 · 10 participants (planned) · Start Oct 26, 2026 · Primary completion Oct 2027
Drug: Analgesic Agent; Lidocaine Topical · For: Renal Pelvis and Ureter Urothelial Carcinoma
Sites: Ann Arbor, Michigan
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05987241 · 992 participants (planned) · Start Feb 2, 2024 · Primary completion Sep 2, 2030
Drug: Nivolumab; Relatlimab · For: Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma and 4 more
Sites: Phoenix, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 505 sites in all
Beijing BiotechIndustry
NCT07492628 · 42 participants (planned) · Start Mar 2, 2026 · Primary completion Jun 14, 2027
Drug: EB-DT-NK-UC101; Cyclophosphamide and 1 more · For: Bladder Cancer; Urothelial Carcinoma; Metastatic Urothelial Carcinoma and 2 more
Sites: Shenzhen, China
Pliant Therapeutics, Inc.Industry
NCT06270706 · 124 participants (planned) · Start Aug 30, 2023 · Primary completion Jun 2030
Drug: PLN-101095; PLN-101095 and 5 more · For: Advanced or Metastatic Solid Tumor
Sites: New Haven, Connecticut; Washington D.C., District of Columbia; Atlanta, Georgia · 27 sites in all
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06770582 · 160 participants (planned) · Start Jun 3, 2025 · Primary completion Feb 1, 2032
Drug: Cisplatin; Fluorouracil and 3 more · For: Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v8
Sites: Tucson, Arizona; Fayetteville, Arkansas; Rogers, Arkansas · 147 sites in all
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Pivotal-lookingRecruiting
Inhibrx Biosciences, IncIndustry
NCT04198766 · 340 participants (planned) · Start Dec 10, 2019 · Primary completion Jul 2033
Drug: INBRX-106 - Hexavalent OX40 agonist antibody; pembrolizumab 200 mg and 8 more · For: Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer and 5 more
Sites: Duarte, California; Glendale, California; La Jolla, California · 60 sites in all
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruiting
PfizerPfizer (PFE)
NCT07090499 · 540 participants (planned) · Start Aug 20, 2025 · Primary completion Jul 8, 2028
Drug: PF-08046876 · For: Advanced/Metastatic Solid Tumors; Bladder Cancer; Urothelial Carcinoma and 10 more
Sites: Duarte, California; Irvine, California; Los Angeles, California · 31 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT05614739 · 677 participants (planned) · Start Jan 12, 2023 · Primary completion Jun 2027
Drug: Vepugratinib; Pembrolizumab and 5 more · For: Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms
Sites: Tucson, Arizona; Duarte, California; Los Angeles, California · 83 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06465069 · 460 participants (planned) · Start Jul 1, 2024 · Primary completion May 2027
Drug: LY4052031; Pembrolizumab · For: Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor and 11 more
Sites: Duarte, California; La Jolla, California; Los Angeles, California · 40 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.